Market Movers: A10 Networks (NYSE:ATEN), Fibrocell Science (NASDAQ:FCSC), PerkinElmer Inc. (NYSE:PKI), MEI Pharma (NASDAQ:MEIP), DaVita HealthCare Partners Inc. (NYSE:DVA)


On Monday shares of A10 Networks, Inc. (NYSE:ATEN) closed at $4.67. Company’s EPS growth for next 5 years is recorded as 23.00%. A10 Networks, Inc. (NYSE:ATEN), announced financial results for its first quarter ended March 31, 2015. Total revenue for the first quarter was $44.0 million, compared with $45.7 million in the first quarter of 2014. A10 Networks first quarter 2015 GAAP net loss was $13.7 million, compared with a GAAP net loss of $5.1 million in the first quarter of 2014.

Fibrocell Science, Inc. (NASDAQ:FCSC) in last trading activity increased 8.67% to close at $3.76. Company weekly performance is 5.62% while its quarterly performance stands at -2.59%. Fibrocell Science, Inc. (NASDAQ:FCSC) is -37.23% away from its 52 week high. Zacks reaffirmed their hold rating on shares of Fibrocell Science (NASDAQ:FCSC) in a report issued on Friday.

On last trading day PerkinElmer Inc. (NYSE:PKI) fell -0.93% to close at $52.06. Its volatility for the week is 2.11% while volatility for the month is 1.33%. PKI’s sales growth for past 5 years was 7.60% and its EPS growth for past 5 years was 17.60%. PerkinElmer Inc. (NYSE:PKI) monthly performance is 2.72%. PerkinElmer Inc. (NYSE:PKI) announced that the Company will present at the Bank of America Merrill Lynch 2015 Healthcare Conference on Wednesday, May 13 at 10:00am PT at the Encore at Wynn in Las Vegas.

MEI Pharma, Inc. (NASDAQ:MEIP) has 0.10% insider ownership while its institutional ownership stands at 81.30%. In last trading activity company’s stock closed at $2.13. MEI Pharma, Inc. (NASDAQ:MEIP), announced new pre-clinical data showing mitochondria-specific effects of the Company’s investigational drug candidate ME-344 in cancer cells, including significantly enhanced anti-tumor activity when combined with a tyrosine-kinase inhibitor (TKI). In addition, a recently published study found ME-344 to be a potent inhibitor of mitochondrial oxidative phosphorylation (OXPHOS) complex I, a direct molecular target.

On Monday shares of DaVita HealthCare Partners Inc. (NYSE:DVA) closed at $82.34. Company’s sales growth for last 5 years was 16.00% and EPS growth for next 5 years is recorded as 8.11%. DaVita Kidney Care, a division of DaVita HealthCare Partners Inc. (NYSE:DVA), on Monday announced the next step in an agreement in principle for a settlement in an Atlanta-based case, which previously was announced on April 15. The lawsuit was brought by private attorneys regarding allegations of medication wastage from 2003 to 2010.


Leave a Reply

Your email address will not be published. Required fields are marked *